Cardenolides from Nierembergia aristata

Area of Science:

• Natural Product Chemistry
• Pharmacology
• Medicinal Botany

Background:

• Nierembergia aristata, an Argentinian plant species, has not been previously investigated for its phytochemical constituents and potential medicinal properties.
• Cardiac glycosides are known for their diverse pharmacological activities, including cardiotonic and anticancer effects.

Purpose of the Study:

• To investigate the cytotoxic potential of Nierembergia aristata extract against various cancer cell lines.
• To isolate and characterize novel cardenolide compounds from Nierembergia aristata.
• To evaluate the anticancer activity of the isolated compounds.

Main Methods:

• Extraction of the whole plant using ethyl acetate (EtOAc).
• Bioassay-guided fractionation to isolate active compounds.
• Structural elucidation of isolated compounds using spectroscopic methods.
• Cytotoxicity assays against eleven different human cancer cell lines.

Main Results:

• The EtOAc extract of Nierembergia aristata exhibited significant cytotoxicity across all eleven tested cancer cell lines.
• Three new cardenolides were successfully isolated and characterized: 17-epi-11 alpha-hydroxy-6, 7-dehydrostrophanthidin-3-O-beta-boivinopyranoside [1], 6, 7-dehydrostrophanthidin-3-O-beta-boivinopyranoside [2], and 6,7-dehydrostrophanthidin-3-O-beta-oleandropyranoside [3].
• Compound [3], 6,7-dehydrostrophanthidin-3-O-beta-oleandropyranoside, demonstrated potent activity against all tested cancer cell lines.

Conclusions:

• Nierembergia aristata is a promising source of novel cytotoxic cardenolides.
• The isolated cardenolides, particularly compound [3], show significant potential for anticancer drug development.
• This study represents the first report of cardiac glycoside isolation from the Solanaceae family, expanding the known phytochemical diversity of this plant family.